Literature DB >> 15030253

Percutaneous implantation of pulmonary valves.

S Khambadkone1, P Bonhoeffer.   

Abstract

Percutaneous implantation of valves is evolving as the most exciting innovation in transcatheter therapeutics. Valve repairs and replacements form an important indication of re-operations after congenital heart operations. Right ventricular outflow tract surgery is common after repair of conditions such as pulmonary atresia with Tetralogy of Fallot, common arterial trunk and Rastelli operation for transposition of great arteries, ventricular septal defect with pulmonary stenosis. Conduit survival is improving, nevertheless, re-operations are common. Although the re-operations can be performed at low risk, they still involve morbidity and mortality. Percutaneous implantation of valves is emerging as an alternative option for these group of patients. Our experience in percutaneous implantation of pulmonary valves has yielded encouraging results. For incompetence, the results are excellent. Evolving technology is making it applicable in wider clinical situations. Similar technology could also be applied to implantation of valves in the aortic position.

Entities:  

Mesh:

Year:  2003        PMID: 15030253     DOI: 10.1586/14779072.1.4.541

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

1.  An ovine model of pulmonary insufficiency and right ventricular outflow tract dilatation.

Authors:  J Daniel Robb; Matthew A Harris; Masahito Minakawa; Evelio Rodriguez; Kevin J Koomalsingh; Takashi Shuto; Yoav Dori; Robert C Gorman; Joseph H Gorman; Matthew J Gillespie
Journal:  J Heart Valve Dis       Date:  2012-03

2.  Percutaneous implantation of the Edwards SAPIEN(™) pulmonic valve: initial results in the first 22 patients.

Authors:  Nikolaus A Haas; Axel Moysich; Ulrich Neudorf; Hojjat Mortezaeian; Mohamed Abdel-Wahab; Heike Schneider; Daniel De Wolf; Jerome Petit; Sreeram Narayanswami; Kai Thorsten Laser; Eugen Sandica
Journal:  Clin Res Cardiol       Date:  2012-08-30       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.